|
|
||||||||
Roswell Park Memorial Institute and State University of New York at Buffalo Medical School, Buffalo, New York
Correspondence: For reprints contact: R. E. Ackerhalt, Dept. of Nuclear Medicine, School of Medicine, State University of New York, 3435 Main St., Buffalo, N.Y. 14214.
ABSTRACT
The advantages of 99mTc-labeled bone-imaging agents have stimulated a considerable amount of work toward the development of these radiopharmaceuticals. A comparison was made of the biologic properties of 99mTc-Sn-polyphosphate, Sn-pyrophosphate, Sn-1-Hydroxyethane-1-diphosphonate (EHDP), and 18F-fluoride.
Three-hour distribution studies were done in rabbits for each radiopharmaceutical. These radiopharmaceuticals were also administered to patients, and scans were obtained between 3 and 4 hr. These scans were evaluated for background activity due to soft-tissue and blood retention. The blood clearance of 99mTc and 18F was also determined in patients.
On the basis of the above experiments, it was concluded that 99mTc bone-imaging radiopharmaceuticals available to date leave something to be desired in their blood and soft-tissue clearance and high kidney uptake. While the physical properties of 18F are poor, the biologic properties are still superior for bone-imaging. The biologic properties of polyphosphate are significantly worse than pyrophosphate or EHDP. These latter two agents are more similar to 18F in their blood clearance and soft-tissue uptake.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |